Further class action lawsuits are pending in the USA against $NOVO B (+0.26%) and $LLY (-0.48%) .
How dangerous is it to take weight loss drugs like Ozempic? There is already a class action lawsuit in the USA. The allegation: the drugs can cause severe gastric paralysis. But that's obviously not all.
In the USA, numerous lawsuits against the pharmaceutical companies Novo Nordisk and Eli Lilly are being consolidated due to allegations of possible serious side effects of their diabetes and weight loss drugs. A competent committee of the US judiciary decided on Monday to bundle the lawsuits before a judge in the state of Pennsylvania due to the risk of blindness.
The plaintiffs allege that drugs such as Ozempic, Wegovy and Trulicity can cause blockage of the blood supply to the optic nerve, leading to partial or complete vision loss. The drugs in question belong to the class of GLP-1 agonists. They were originally developed for the treatment of diabetes, but are increasingly being prescribed for weight loss.
The new class action is being heard separately from an existing, extensive class action. In the latter, plaintiffs allege that the drugs can cause severe gastric paralysis. However, both proceedings are being conducted by the same judge.
According to court records, there are currently 30 lawsuits alleging blindness at the federal level and more than 40 in the individual states. The class action lawsuit over stomach problems, on the other hand, includes nearly 3,000 cases. The companies reject the allegations. They argue that the risks are known. In addition, it is not possible to change the design of the drugs without the approval of the US Food and Drug Administration (FDA). The lawyers have not yet issued a statement.
Compensation for four patients in Denmark
In Denmark, four patients received compensation in November because they had developed serious eye diseases after taking weight loss or diabetes medication. As the Danish Patient Compensation Authority decided, the four patients concerned will receive a total compensation payment of 800,000 Danish kroner (equivalent to around 107,000 euros). The patients had each used the weight loss drug Wegovy or the diabetes drug Ozempic, both of which are manufactured by the Danish pharmaceutical company Novo Nordisk.
Depending on what impact the disease will have on their future lives - for example, if it affects their ability to work - the compensation payments could still increase, the authority explained. Medical compensation in Denmark is usually paid out by the health authorities. In total, more than 40 people have claimed compensation after developing serious eye diseases after using the drugs. The authority has so far ruled in five cases.
https://www.n-tv.de/wirtschaft/Weitere-Sammelklage-gegen-Ozempic-Hersteller-id30147418.html
